

**AMENDMENT TO THE CLAIMS**

1-36. **(Canceled)**

37. **(Currently Amended)** A method for reducing tissue factor levels to treat a cancer exhibiting tissue factor expression, comprising administering to a mammal a therapeutically effective amount of an antibody that comprises a sequence represented by SEQ ID NO: 2 or SEQ ID NO:4, or fragment thereof, that binds native human tissue factor to form a complex, whereby Factor X binding to the complex is inhibited and Factor VII or VIIa binding to tissue factor is not inhibited.

38. **(Canceled)**

39. **(Previously Presented)** The method of claim 37, wherein the antibody or fragment has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 deposited as ATCC HB12255.

40. **(Previously Presented)** The method of claim 37, wherein the antibody has identifying characteristics of H36.D2.B7 deposited as ATCC HB-12255.

41. **(Previously Presented)** The method of claim 37, wherein the antibody is H36.D2.B7 deposited as ATCC HB- 12255.

42. **(Previously Presented)** The method of claim 37, wherein the antibody is a monoclonal antibody.

43. **(Currently Amended)** The method of claim 37, wherein the antibody is a chimeric antibody.

44. **(Currently Amended)** The method of claim 6543, wherein the chimeric antibody further comprises a constant region of human origin.

45. **(Currently Amended)** The method of claim 6637, wherein the humanized antibody comprises at least one hypervariable regions of non-human origin.

46. **(Previously Presented)** The method of claim 37, wherein the antibody is a single chain antibody.

47. - 53. **(Canceled)**

54. **(Previously Presented)** The method of claim 37, wherein the fragment is a Fab, F(v), Fab', or F(ab')<sub>2</sub> fragment.

55. **(Previously Presented)** The method of claim 37, wherein the Factor X binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

56. **(Previously Presented)** The method of claim 37, wherein the Factor X binding to the complex is inhibited by at least 90 percent in a standard in vitro binding assay.

57. **(Previously Presented)** The method of claim 37, wherein the Factor X binding to the complex is inhibited by at least 95 percent in a standard in vitro binding assay.

58. **(Previously Presented)** The method of claim 37, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.

59. **(Previously Presented)** The method of claim 37, wherein administration of the antibody increases the clotting time by at least 150 percent according to a prothrombin time (PT) assay.

60. **(Previously Presented)** The method of claim 37, wherein administration of the antibody increases the clotting time by at least 300 percent according to a prothrombin time (PT) assay.

61. - 64. **(Canceled)**

65. **(Previously Presented)** The method of claim 43, wherein the chimeric antibody comprises a mouse variable region.

66. **(Previously Presented)** The method of claim 37, wherein the antibody is a human or humanized antibody.

67. **(Previously Presented)** The method of claim 37, wherein the antibody fragment is derived from a humanized or chimeric antibody.

68. **(Canceled)**